References
Parthenakis FI, Patrianakos A, Prassopoulos V, Papadimitriou E, Nikitovic D, Karkavitsas NS, Vardas PE. Relation of cardiac sympathetic innervation to proinflammatory cytokine levels in patients with heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2003; 91:1190–1194.
Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy—clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J. 2001; 141:645–652.
Choi JY, Lee KH, Hong KP, Kim BT, Seo JD, Lee WR, Lee SH. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol. 2001; 8:4–9.
Shinohara H, Fukuda N, Soeki T, Sakabe K, Onose Y, Tamura Y. Effects of angiotensin II receptor antagonists on [123I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure. Heart Vessels. 2002; 17:47–52.
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003; 44:884–890.
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:574–581.
Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471–477.
Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J 2002; 66:537–543.
Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003; 9:384–391.
Nishimura T, Sugishita Y, Sasaki Y. The results of questionnaire on quantitative assessment of123I-metaiodobenzylguanidine myocardial scintigraphy in heart failure. Kaku Igaku 1997; 34:1139–1148.
Motomura N, Ichihara T, Takayama T, Aoki S, Kubo H, Takeda K. Practical compensation method of downscattered component due to high energy photon in123I imaging. Kaku Igaku 1999; 36:997–1005.
Kobayashi H, Momose M, Kanaya S, Kondo C, Kusakabe K, Mitsuhashi N. Scatter correction by two-window method standardizes cardiac I-123 MIBG uptake in various gamma camera systems. Ann Nucl Med 2003; 17:309–313.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamashina, S., Yamazaki, Ji. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 31, 1353–1355 (2004). https://doi.org/10.1007/s00259-004-1493-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-004-1493-1